RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
CRISPR-Powered cell therapy takes on Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment called CB-011 for people with multiple myeloma that has returned or stopped responding to other therapies. CB-011 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The study aims to find the saf…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 06:23 UTC
-
Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack two targets (CD19 and B…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 06:18 UTC
-
New drug duo aims to tackle Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if the combination is safer and works better than linv…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 06:17 UTC
-
New hope for tough blood cancer: targeted drug combo trial opens
Disease control Recruiting nowThis study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or not responded to treatment. The goal is to see if the drug is safe and helps shrink the cancer. About 246 adults with a specific genetic …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 06:16 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, boosted with a protein called IL-15, in people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The goal is to see if these enhanced immune cells can shrink or eliminate the cancer. …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 17, 2026 06:14 UTC
-
New CAR-T therapy targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CT0596 CAR-T cells for people with multiple myeloma or plasma cell leukemia that has come back or not responded to standard therapies. The main goals are to check safety and find the right dose. About 24 adults will take part, a…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Tough-to-Treat multiple myeloma: LBL-034 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called LBL-034 in people whose multiple myeloma has returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 342 adults will take part in this early-phase trial ac…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New shot combo aims to control hard-to-treat blood cancer
Disease control Recruiting nowThis study tests a new combination of two drugs (elranatamab and isatuximab) given as shots under the skin for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. About 30 adults will take part. The goal is to see if the combo c…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New CAR-T therapy aims to outperform standard drugs in Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on myeloma cells. It is compared to standard drug combinations in about 508 adults with multiple myeloma that has returned or not responded t…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New hope for hard-to-treat myeloma: experimental drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called cemsidomide combined with dexamethasone in 100 adults whose multiple myeloma has returned or stopped responding after at least three prior treatments. The goal is to see how well the combination shrinks tumors and how safe it is. Participants wi…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New cell therapy takes aim at Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called IMV102 in 30 people with multiple myeloma that has returned or not responded to at least three prior therapies. Participants receive a single infusion of their own modified immune cells. The main goal is to check safety, and res…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New hope for Tough-to-Treat myeloma: first human trial of ISB 2001 launches
Disease control Recruiting nowThis early-stage study tests a new drug called ISB 2001 in about 200 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. Participants will receive the drug and be closely m…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Ichnos Sciences SA • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
Researchers track Real-Life results for blood cancer treatments
Knowledge-focused Recruiting nowThis study aims to observe how standard treatments for relapsed multiple myeloma work in everyday clinical practice. Researchers will follow 300 patients for two years to track treatment effectiveness, safety, and how patients feel. The study is observational, meaning it watches …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated Apr 22, 2026 15:59 UTC